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CD341 CELL YIELD ON DAY 1 OF APHERESIS PREDICTS TOTAL CD341
CELL MOBILIZATION, NEUTROPHIL RECOVERY, AND SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA
Dean, R.1, Rybicki, L.2, Pohlman, B.1, Sweetenham, J.1, Sobecks, R.1,
Copelan, E.1, Kalaycio, M.1, Smith, S.1, Andresen, S.1, Bolwell, B.1
1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 2Cleveland
Clinic Taussig Cancer Institute, Cleveland, OH
Lymphoma patients who mobilize CD341 cells poorly have infe-
rior outcomes after autologous stem cell transplantation (ASCT).
Identifying poor mobilizers early may allow intervention (e.g., add-
ing plerixafor) to improve mobilization. We retrospectively com-
pared CD341 cell yields on day 1 (D1) of autologous stem cell
collection with the total CD341 cell yield and with ASCT outcomes
including neutrophil (ANC) recovery .500 cells/ul, nonrelapse
mortality (NRM), relapse-free survival (RFS), and overall survival
(OS). Patients (n 5 411) underwent ASCT at a single center from
1998 through 2007. Diagnoses were Hodgkin lymphoma (n 5 83),
aggressive B-cell NHL (n 5 196), indolent B-cell NHL (n 5 64),
mantle cell NHL (n5 37), or T-cell NHL (n5 31). All were mobi-
lized with etoposide 2 g/m2 and filgrastim 10 ug/kg. After WBC re-
covery to 1000/uL, leukapheresis commenced for$2 days and up to
5 days, to a target dose of $7 (minimum $2) million CD341 cells/
kg. Conditioning for ASCT was high-dose busulfan, cyclophospha-
mide, and etoposide. Median follow-up among 248 survivors is 42
months. Causes of death were relapse (66%), NRM (28%) and un-
known (6%). Total CD341 cell yield was median 8.82 million/kg
(range, 2 to 162) in 3 days of apheresis (range, 2 to 20). Median
D1 yield was 1.98 million CD341 cells/kg (range, 0 to 120). The
D1 yield was strongly correlated with total CD341 cell yield (R 5
0.87, P\0.001) and days of apheresis required (R 520.87,
P\0.001). Higher D1 yield (by patient quintiles) was associated in
univariable analyses with faster ANC recovery after ASCT
(P\0.001), lower NRM (P 5 0.03), better OS (P 5 0.03, P 5
0.001, and P\0.01 for quintiles 3, 4, and 5 vs. quintile 1), and better
RFS (P\0.01 and P 5 0.04 for quintiles 4 and 5). In multivariable
analyses, D1 yield and Karnofsky performance status (KPS) were
prognostic for NRM; D1 yield, KPS, lymphoma histology, number
of prior chemotherapy regimens, and pre-ASCT disease status were
prognostic for RFS; and D1 yield, age, KPS, histology, number of
prior regimens, and number of days of apheresis were prognostic
for OS. These data extend our prior observation that stem cell mo-
bilization is associated with ASCT outcomes in lymphoma patients.
The D1 CD341 cell yield predicts the total CD341 cell yield, ANC
recovery after ASCT, NRM, and survival. Poor mobilizers are iden-
tifiable on D1 of CD341 cell collection and represent a patient sub-
group in which to test interventions to improve mobilization and
potentially other ASCT outcomes.
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DAY 15 INTERLEUKIN 15 LEVELS AFFECT NATURAL KILLER CELL RE-
COVERY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Porrata, L.F., Inwards, D.J., Micallef, I.N., Johnston, P.B., Ansell, S.M.,
Markovic, S.N. Mayo Clinic, Rochester, MN
Recently, we reported in a prospective study (Porrata et al. Biology
of Blood & Marrow Transplantation 2008;14(7):807–16) that the ab-
solute number of natural killer (NK) cells at day 15 post-autologous
stem cell transplantation (ASCT) affects survival. Factors affecting
NK cell recovery at day 15 post-ASCT are not completely under-
stood. Interleukin-15 (IL-15) is a cytokine associated with NK cell
differentiation and homeostasis. Thus, we studied the role of day
15 IL-15 on NK cell recovery post-ASCT. From February 2002 to
February 2007, 50 non-Hodgkin lymphoma (NHL) patients enrolled
in the study. We identified higher levels of day 15 IL-15 compared
with normal controls and pre-ASCT IL-15 levels [normal IL-15
levels: median 5 0 pg/ml (range: 0–3.37 pg/ml); pre-ASCT IL-15
levels: median 5 0.09 pg/ml (range: 0–229.42 pg/ml); and day 15
IL-15: median 5 5.48 pg/ml (range: 0–36.94), p\ 0.0001)]. ROC
curve and AUC analysis showed that day 15 IL-15 was a significant
marker for NK cell recovery (AUC5 0.87, p\0.0001). The best cut-
off level was 9.5 pg/ml. Groups (#9.5 or.9.5 pg/ml) were balanced
in regard to histology (p 5 0.48); gender (p 5 0.8); stage (p 5 0.7);
LDH (p5 0.5); disease status prior to ASCT (p5 0.9); performance
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MOBILIZATIONWITH CHEMOTHERAPY COMPARED TO G-CSF ALONE: AN
ANALYSIS OF RESOURCE USE AND COST IN AUTOLOGOUS STEM CELL
TRANSPLANT PATIENTS
Pelletier, E.M.1, Smith, P.J.1, Dembek, C.J.2 1 IMS Consulting, Water-
town, MA; 2Genzyme Corporation, Cambridge, MA
Objectives: The most common mobilization regimens for autol-
ogous stem cell transplant (ASCT) are granulocyte-colony stimulat-
ing factor (G-CSF) alone or in combination with chemotherapy.
Chemotherapy plus G-CSF has been shown to mobilize more cells
than G-CSF alone but often at the expense of costly side effects.
The purpose of this study was to evaluate resource use and cost
during mobilization for patients mobilized with chemotherapy plus
G-CSF vs. G-CSF alone.
Methods: Patients 18 years of age or older with evidence of ASCT
between January 1, 2000 and December 31, 2006 were identified
from a nationally-representative database of private payer medical
and pharmacy claims. Patients had to receive apheresis within 60
days prior to ASCT and have a history of multiple myeloma, non-
Hodgkin’s lymphoma, or Hodgkin’s disease; patients also were
required to be continuously enrolled in one health plan for at least
90 days pre-ASCT and have no evidence of a prior ASCT. Using
claims data, patients were classified into one of two mobilization
regimens: G-CSF alone or chemotherapy with G-CSF. Total
resource use and direct medical costs were calculated from the
time of administration of the mobilization regimen to the first apher-
esis day; paid claims were used as a proxy for costs and expressed in
2006 US$.
Results: 235 ASCT patients were identified; 172 (73%) were
mobilized with G-CSF alone and 63 (27%) with chemotherapy
and G-CSF. Total mobilization costs were 27% higher among
patients mobilized with chemotherapy versus those mobilized
with G-CSF alone ($39,686 vs. $31,251, P 5 0.020). Patients
mobilized with chemotherapy had higher inpatient hospital costs
($8,225 vs. $5,854, P 5 0.056), more use of growth factor
($9,217 vs. $6,948, P 5 0.003), and higher pharmacy costs
($5,343 vs. $1,484, P\0.001) than patients mobilized with G-
CSF alone. Rituximab comprised 48% of pharmacy costs in
the chemotherapy and G-CSF group, while the remaining costs
were due to chemotherapy drugs, MESNA, and anti-emetics. Ex-
cluding rituximab and G-CSF, patients mobilized with chemo-
therapy had pharmacy costs that were $1,645 higher than
patients mobilized with G-CSF alone.
Conclusion: ASCT patients mobilized with chemotherapy had
higher total mobilization costs than patients mobilized with G-
CSF alone. This significant difference in costs was due to more costly
hospitalizations and greater use of G-CSF and other pharmaceuti-
cals in patients mobilized with chemotherapy.
Total Mobilization Costs for Chemotherapy and G-CSF vs.
G-CSF Alone
Chemotherapy
and G-CSF G-CSF Alone
Mean (SD) Mean (SD) % Difference P-value
Total
Mobilization
Costs
$39,686 (31,188) $31,251 (31,750) 27% 0.020
Inpatient $8,225 (19,214) $5,854 (18,312) 41% 0.056
Outpatient $16,901 (17,085) $16,965 (19,772) 0% 0.971
Pharmacy $14,560 (12,067) $8,432 (13,502) 73% \0.001
- G-CSF $9,217 (7,069) $6,948 (10,514) 33% 0.003
- Rituximab $2,547 (6,228) $332 (1,625) 667% \0.001
- Other retail
pharmacy
$2,797 (2,923) $1,152 (2,644) 143% \0.001
